Real Housewives star, 45, diagnosed with breast cancer after 'alert' from body
The Real Housewives of Atlanta star Monyetta Shaw-Carte has revealed that she has secretly battled breast cancer - undergoing surgery and radiotherapy earlier this year
Real Housewives of Atlanta star Monyetta Shaw-Carte has revealed she is battling cancer. The 45-year-old reality star has appeared on the Atlanta version of the hugely successful franchise since 2022.
She appears on the series alongside the main Housewives Atlanta stars including Shereé Whitfield, Kenya Moore and Shamea Morton Mwangi. Monyetta has revealed that she has been battling a health condition in secret.
She has revealed that she was diagnosed with stage 1 invasive ductal carcinoma in November 2024, but had also had concerns about breast cancer a decade before. She has shared details of her health fight while also raising awareness of the importance of self-checking.
Monyetta told People magazine:"I had a biopsy about 10 years ago and it came back benign Then last year in September I was doing a self-check because I felt this random sensation that I can't really describe in my left boob.
"It was like nothing I've ever felt before. It was literally like my body was alerting me that something was wrong." The following month, the TV star was attending a routine mammogram when a lump was discovered.
She underwent surgery to remove the growth in January this year and then underwent a gruelling 16 rounds of radiation treatment. The medical steps have, however, proved to be successful, and she was able to ring the bell at her treatment at the beginning of last month, marking the end of her treatment.
She said: "Because I caught the cancer early, I will be here for my kids. There's nothing more important than getting checked often and early to protect your future." She added: "Our health is irreplaceable. I can't thank my exceptional doctors and nurses enough. They are our heroes.'
Breast cancer is the most common form of cancer in the UK, with Cancer Research UK noting that 56,800 new breast cancer cases are recorded in the UK each year. The disease is highly treatable, especially when detected early.
While the cause of breast cancer is still not fully understood, it is more common in women over the age of 50, can affect those who have a history of the disease in the family, and can affect those who have an existing condition such as benign breast disease, ductal carcinoma in situ or lobular carcinoma in situ.
Doctors and scientists have also tracked that those who carry the BRCA1 gene are more susceptible to breast cancer. It is possible to be tested for the gene, and preemptive surgery can be undertaken.
American actress Dame Angelina Jolie underwent a double mastectomy in February 2013 after learning she carried the gene. She revealed she had undergone the procedure to help raise awareness of breast cancer and the available treatments.
She said at the time: "I choose not to keep my story private because there are many women who do not know that they might be living under the shadow of cancer.
"It is my hope that they, too, will be able to get gene tested, and that if they have a high risk they, too, will know that they have strong options." Angelina lost her mother, Marcheline Bertrand, in 2007 as she died at the age of 56 after battling ovarian and breast cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Doctors discover food that prevents heart disease and diabetes... and 90% of Americans don't eat enough of it
Regularly eating a combination of fruits, vegetables, nuts and whole grains may reduce your risk of developing two of the most deadly chronic diseases, a study suggests. A group of American researchers discovered phytosterols, a compound found naturally in a variety of foods like nuts, seeds, grains and vegetable oils, can help improve metabolism and reduce inflammation - keeping both heart disease and type 2 diabetes at bay. However, up to 90 percent of Americans don't eat the recommended daily serving of fruits, vegetables, nuts and whole grains. Phytosterols are compounds similar to cholesterol and are promoted as a way to improve heart health and decrease blood levels of LDL (bad) cholesterol as they are known to absorb the fat-like substance. Now, the new study suggests high phytosterol intake can also improve insulin regulation, reduce heart inflammation and contribute to a healthy metabolism. Type 2 diabetes is the most common form of diabetes globally and over 37million American adults suffer from it. The American Heart Association reports about 48 percent of Americans are living with some type of cardiovascular disease and CVD is the number one killer in the US - accounting for about one in five deaths. Dr Fenglei Wang, lead author and research associate at Harvard University, said the findings support claims that eating a healthy plant-based diet with plenty of vegetables and whole grains can be beneficial for humans. While phytosterols are found in all plant foods, the highest concentrations are found in unrefined plant oils, including vegetable, nuts and olive oils. Nuts such as almonds, pistachio and cashews; seeds such as pumpkin, sunflower and watermelon; whole grains such as oats and barley as well as legumes such as chickpeas, lentils and soybeans are also good dietary sources of phytosterols. The compound is also found in vegetables such as artichokes, broccoli, green beans, sweet potatoes and cauliflower as well as fruits such as pineapples, oranges, berries and bananas. The researchers followed over 200,000 American adults for 36 years. The participants were asked to periodically answer questionnaires on dietary intake to measure how much phytosterol-rich food they were consuming. Their answers were then evaluated using a variety of statistical models to discover their likelihood of developing Type 2 diabetes and heart disease. During the follow-up period, the researchers noted over 20,000 study participants developed Type 2 diabetes and nearly 16,000 developed heart disease. Results showed those who consumed about five servings of vegetables, three servings of fruit, two servings of whole grains and half a serving of nuts - all of which are high in phytosterols - per day were about 10 percent less likely to develop either conditions. But nearly no American reaches these benchmarks. The researchers also analyzed metabolites - products of metabolism - and other metabolic biomarkers present in blood samples from about 40,000 people to understand the effect of phytosterols on the calorie-burning process. They discovered those who consumed phytosterols had better metabolism - which helped control insulin levels and inflammation around the heart. Dr Wang noted the results showed consuming phytosterols may reduce the risk for Type 2 diabetes by reducing insulin resistance in the body and stave off heart disease by preventing inflammation. The foods studied as part of the research are recommended as part of a healthy and well-rounded diet and have been linked to multiple health benefits also because of their antioxidants and fiber. The scientists in the most recent study, however, did not specify how they observed the benefits stemmed from the consumption of phytosterols specifically. The study was presented today at the Bioactives for Brain and Cardiometabolic Health session in Orange County, Florida and will later be published in the journal Nutrition.
The Independent
4 hours ago
- The Independent
Brits more likely to develop cancer but less likely to die: report
Cancer death rates in the UK have fallen by 22 per cent since the early 1970s, but cancer diagnoses have increased by 47 per cent in Great Britain during the same period, according to Cancer Research UK. The decline in cancer deaths is attributed to advancements in diagnosis and treatment, as well as initiatives to reduce smoking. Michelle Mitchell, Cancer Research UK 's chief executive, described the findings as a time of 'optimism and realism,' highlighting that it is also 'a golden age for cancer research'. Smoking is identified as the leading preventable cause of cancer, with obesity linked to 13 different types of the disease. MPs and members of the House of Lords are urging the Government to prioritise faster diagnosis of less survivable cancers, which account for approximately 42 per cent of cancer deaths.
NBC News
4 hours ago
- NBC News
Wegovy use among U.S. teens up 50% as obesity crisis worsens
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows. The average rate of teens beginning treatment with the highly effective Novo Nordisk drug grew 50% last year to 14.8 prescriptions per 100,000 adolescents, according to an analysis by health data firm Truveta. That's up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children aged 12 and older. The average rate climbed further during the first three months of this year, reaching 17.3 new prescriptions per 100,000. That still represents a minute fraction of the estimated 23,000 out of every 100,000 teens in the country who are living with obesity, and is far slower than the uptake among U.S. adults. 'It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them,' said Dr. Cate Varney, director of obesity medicine at the University of Virginia Health system. 'When lifestyle changes alone are insufficient, we need these additional tools.' For its analysis, Truveta reviewed the electronic health records of 1.3 million patients ages 12 through 17. The data covers 30 U.S. health systems with more than 900 hospitals and 20,000 clinics across the country. The analysis did not include other GLP-1 drugs, including Novo's Ozempic and Eli Lilly's LLY.N Zepbound, which are not approved to treat obesity in adolescents, or compounded versions of these therapies. Wegovy became an option to treat adolescents in late 2022 after decades in which the conventional approaches of diet, exercise and counseling largely failed. About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S. government data. Young people with obesity run a much higher risk of developing chronic, costly, life-shortening conditions like type 2 diabetes and cardiovascular and liver diseases. In January 2023, the American Academy of Pediatrics strongly recommended that doctors provide weight-loss drugs to children with obesity starting at age 12. Yet the medical community has not uniformly embraced GLP-1s for adolescents. Some doctors are hesitant because the drugs' long-term safety for children during a critical phase of development is unknown, and the treatments may need to be used indefinitely. Overall, there are limited options for many teens and their parents because insurance plans often do not cover any treatment for obesity, including intensive behavioral counseling, visits with a dietician or the new GLP-1 medications. At Nemours Children's Hospital in Wilmington, Delaware, the Healthy Weight and Wellness Clinic treated about 2,000 adolescent patients last year. About 25% were prescribed Wegovy or another GLP-1 medication, said Dr. Thao-Ly Phan, the clinic's medical director. The number of adolescents with a GLP-1 prescription nearly doubled from 2023. On average, their patients taking a GLP-1 drug lost 15 pounds (6.8 kg) within 6 to 12 months, and nearly 30 pounds after more than a year. For many of the other patients, the medications were not an option, either because of insurance hurdles or concern within families about potential risks. Other teens opted for lifestyle changes or older, cheaper weight-loss drugs, with some success. 'It is important for us to continue to monitor and better understand outcomes from the medications — both positive and negative — before widespread use,' Phan said. U.S. Health Secretary Robert F. Kennedy Jr. has criticized the idea of prescribing Ozempic or Wegovy widely to children to treat obesity. In a federal health report he released last month, GLP-1 drugs were cited as an example of the 'overmedicalization of our kids.' It noted a lack of 'long-term safety data, raising the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development.' Novo in a statement said semaglutide, the active ingredient in Wegovy and Ozempic, 'did not appear to affect growth or pubertal development' during its clinical trials involving teens. For many adults, Novo said, obesity starts in childhood or adolescence, and 'we are confident in the proven safety and efficacy of our GLP-1 medicines.' Eli Lilly's weight-loss drug Zepbound is in late-stage clinical trials for use by adolescents. Lilly told Reuters that 'there has been no evidence to date suggesting impairment in growth or metabolism' from GLP-1 medications. Dr. Robert Siegel, a pediatrician and director of the Center for Better Health and Nutrition at Cincinnati Children's Hospital, said about 15% of adolescents being treated there were prescribed Wegovy or a similar GLP-1 medication from July 2021 to July 2023. They include patients being treated for type 2 diabetes for which the GLP-1 drugs were originally developed. Siegel said he prefers to start teens on three to six months of intensive lifestyle management before even considering medication. While obesity specialists can help navigate potential risks from the drugs, many primary-care providers need more training, he said. They may not have the equipment to monitor for the loss of muscle mass — a side effect of these medicines — or lack the resources to work with families over an extended period on healthier eating and exercise. 'These medications are likely to be needed for a very long time to maintain weight,' Siegel said, 'and we only have a relatively short-term experience with them.'
